| Dr Stephen Richard Griffith, MD | |
|
105 Valley West Dr, Suite 100, West Des Moines, IA 50265-3902 | |
| (515) 223-4368 | |
| (515) 453-2368 |
| Full Name | Dr Stephen Richard Griffith |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 39 Years |
| Location | 105 Valley West Dr, West Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790773679 | NPI | - | NPPES |
| 1790773679 | Medicaid | IA | |
| 0426205 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 35480 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Knoxville Hospital & Clinics | Knoxville, IA | Hospital |
| Mercyone Des Moines Medical Center | Des moines, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Ent Center Pllc | 6406007608 | 15 |
News Archive
A compact PET scanner called NuPET has been commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.
Researchers have found a better way to predict self-injurious behavior by using a test that does not rely on the individual to articulate their thoughts, but instead assesses their implicit attitudes towards self-injury.
A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.
› Verified 6 days ago
| Entity Name | Knoxville Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770591661 PECOS PAC ID: 6608787056 Enrollment ID: O20031119000804 |
News Archive
A compact PET scanner called NuPET has been commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.
Researchers have found a better way to predict self-injurious behavior by using a test that does not rely on the individual to articulate their thoughts, but instead assesses their implicit attitudes towards self-injury.
A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.
› Verified 6 days ago
| Entity Name | Iowa Ent Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528314960 PECOS PAC ID: 6406007608 Enrollment ID: O20121116000354 |
News Archive
A compact PET scanner called NuPET has been commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.
Researchers have found a better way to predict self-injurious behavior by using a test that does not rely on the individual to articulate their thoughts, but instead assesses their implicit attitudes towards self-injury.
A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen Richard Griffith, MD 105 Valley West Dr, Suite 100, West Des Moines, IA 50265-3902 Ph: (515) 223-4368 | Dr Stephen Richard Griffith, MD 105 Valley West Dr, Suite 100, West Des Moines, IA 50265-3902 Ph: (515) 223-4368 |
News Archive
A compact PET scanner called NuPET has been commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.
Researchers have found a better way to predict self-injurious behavior by using a test that does not rely on the individual to articulate their thoughts, but instead assesses their implicit attitudes towards self-injury.
A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.
› Verified 6 days ago
Dr. Danielle Sonia Liudahl, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5950 University Ave Ste 265, West Des Moines, IA 50266 Phone: 515-875-9450 Fax: 515-875-9457 | |
Douglas R Hoisington, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2600 Westown Pkwy Ste 360, West Des Moines, IA 50266 Phone: 515-267-1800 Fax: 515-267-8857 | |
Dr. Richard Boyd Merrick, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 5950 University Ave, Ste 265, West Des Moines, IA 50266 Phone: 515-875-9450 Fax: 515-875-9457 | |
Timothy C Simplot, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 105 Valley West Dr, Ste 100, West Des Moines, IA 50265 Phone: 515-223-4368 Fax: 515-453-2368 | |
Dr. Brett James Baldwin, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5950 University Ave Ste 265, West Des Moines, IA 50266 Phone: 515-875-9450 Fax: 515-875-9457 | |
Maher Younes, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1455 29th St, West Des Moines, IA 50266 Phone: 515-267-1800 Fax: 515-267-8857 | |
Thomas O Paulson, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 105 Valley West Dr, Suite 100, West Des Moines, IA 50265 Phone: 515-223-4368 Fax: 515-453-2368 |